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A b s t r a c t  
In the present research work mucoadhesive microspheres of cimetidine was prepared using 
ionotropic gelation technique. All the microspheres were characterized for particle size, scanning 
electron microscopy, FT-IR study, DSC, percentage yield, drug entrapment, stability studies and 
for in vitro release kinetics and found to be within the limits. Among all the formulations M12 was 
selected as optimized formulation based on the physicochemical and release studies.            In 
vitro drug release study of optimized formulation M12 showed 99.12% after 12 h in a controlled 
manner, which is essential for anti ulcer therapy. The innovator cimetine conventional tablet showed 
the drug release of 96.15% within 1 h. The drug release of cimetidine optimized formulation M12 
followed zero order and Higuchi kinetics indicating diffusion controlled drug release. In vivo studies 
revealed that the optimized formulation M12 gave the highest AUC and Tmax. The results are 
indicative of cimetidine as mucoadhesive microspheres for improving the oral bioavailability with 
controlled drug release. 
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Introduction 
Oral route is most sought-after for administration of drug molecules 
to the systemic circulation due to low cost therapy, ease of 
administration, patient compliance [1]. New drug delivery 
technologies are revolutionizing the drug discovery, development 
and creating R&D focused pharmaceutical industries to increase 
the momentum of global advancements. In this regard novel drug 
delivery systems (NDDS) have many benefits, which includes 
improved therapy by increasing the efficacy and duration of drug 
activity, increased patient compliance through decreased dosing 
frequency and convenient routes of administration and improved 
site specific delivery to reduce unwanted adverse effects [2].  
Despite the problem frequently encountered with controlled release 
dosage forms is the inability to increase the residence time of the 
dosage form in the stomach and proximal portion of the small 
intestine, due to the rapid gastrointestinal transit phenomenon of 
the stomach which may consequently reduce the extent of 
absorption of many drugs since almost most of the drug entities are 
mostly absorbed from the upper part of the intestine, therefore it 
would be beneficial to develop a sustained release formulation 
which remain at the absorption site for an extended period of time 
so that maximum of dose is absorbed in systemic circulation. 
Several approaches have been immersed to prolong the residence 
time of the dosage forms at the absorption site and one of these is 
the development of oral controlled release mucoadhesive system. 
Various gastrointestinal mucoadhesive dosage forms, such as  
 
 
microspheres and tablets, have been thoroughly prepared and 
reported by several research groups [3,4].  
Mucoadhesion is the relatively new and emerging concept in drug 
delivery. Mucoadhesion keeps the delivery system adhering to the 
mucous membrane [5]. 
Peptic ulcer disease is a break in the lining of the stomach, first part 
of the small intestine or occasionally the lower esophagus [6].  
Cimetidine is  histamine H2-receptor antagonists, which is used to 
reduce the risk of stomach ulcers in patients treated 
with nonsteroidal anti-inflammatory drugs, which has less 
bioavailability (60%) and lesser half life of 2 h [7]. The aim of 
present work is to design and evaluate mucoadhesive 
microspheres of cimetidine in vitro and in vivo to enhance its 
bioavailability and prolong residence time in stomach. 
 
Materials and Methods 
 
Materials 
 
Cimetidine pure drug was generous gift from Aurobindo Pharma 
Limited, Hyderabad, India. Sodium alginate was obtained from 
Pruthvi Chemicals, Mumbai. Sodium alginate, chitosan, xanthan 
gum, kondagogu gum and sodium CMC were gifted from MSN 
Labs Ltd., Hyderabad. All other chemicals used were of analytical 
grade. 
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Formulation of Cimetidine mucoadhesive microspheres 
 
Cimetidine mucoadhesive microspheres were prepared using 
different polymers like sodium alginate, chitosan, sodium CMC, 
xanthan gum and gum kondagogu by ionotropic gelation method. 
Different formulation trials of cimetidine were prepared using 
different concentrations of polymer and cross linking agent. Total 
14 formulations were developed using different polymers in 
different concentrations. In this method, weighed quantity of 
cimetidine was added to 100 ml sodium alginate solution and 
thoroughly mixed at 500 rpm. Resultant solution was extruded drop 
wise with the help of syringe and needle into 100 ml aqueous 
calcium chloride solution and stirred at 100 rpm. After stirring for 10 
min the obtained microspheres were washed with water and dried 
at 60oC ă 2 h in a hot air oven and stored in desciccator [8]. 
 
     Table 1:  Formulation trials for Cimetidine mucoadhesive microspheres 
FORMULATION 
CODE 
CIMETIDINE 
(g) 
SODIUM 
ALGINATE 
SODIUM 
CMC(mg) 
CALCIUM 
CHLORIDE 
XANTHAN 
GUM 
GUM 
KONDAGOGU 
M1 2 1 % 100 7% 1% 0.5%
M2 2 1.2 % 150 7%  1.2% 0.5%
M3 2 1.4% 200 7% 1.4% 0.5%
M4 2 1.6% 250 7% 1.6% 0.5%
M5 2 1.8% 300 7% 1.8% 0.5%
M6 2 2% 350 7% 2% 0.5%
M7 2 2.2% 400 7% 2.2% 0.5%
FORMULATIN 
CODE 
CIMETIDINE 
(g) 
SODIUM 
ALGINATE 
CHITOSAN
(mg) 
CALCIUM 
CHLORIDE 
XANTHAN 
GUM 
GUM 
KONDAGOGU 
M8 2 1% 10 10% 1% 0.5% 
M9 2 1.2% 15 10% 1.2% 0.5% 
M10 2 1.4% 20 10% 1.4% 0.5% 
M11 2 1.6% 25 10% 1.6% 0.5% 
M12 2 1.8% 30 10% 1.8% 0.5%
M13 2 2% 35 10% 2% 0.5%
M14 2 2.2% 40 10% 2.2% 0.5%
 
Evaluation studies of Cimetidine mucoadhesive 
microspheres 
 
Micromeretic parameters like particle size9, angle of repose, bulk 
density, tapped density, compressibility index, HausnerÊs ratio [10], 
swelling index [11], drug entrapment efficiency and % yield [12]. 
 
Mucoadhesiveness 
 
The in vitro mucoadhesive test was carried out using small intestine 
from chicken. The small intestinal tissue was excised and flushed 
with saline. Five centimeter segments of jejunum were averted 
using a glass rod. Ligature was placed at both ends of the 
segment. 100 microspheres were scattered uniformly on the 
averted sac from the position of 2 cm above. Then the sac was 
suspended in a 50 ml tube containing 40 ml of saline by the wire, to 
immerse in the saline completely. The sacs were incubated at 370C 
and agitated horizontally. The sacs were taken out of the medium 
after immersion for 1, 2, 3, 4, 5, 6, 7 and 8 h, immediately 
repositioned as before in a similar tube containing 40 ml of fresh 
saline and unbound microspheres were counted. The adhering 
percent was presented by the following equation [13].  
Mucoadhesion= (No. of microspheres adhered/ No. of 
microspheres applied) x 100 
 
In vitro drug release studies 
 
In vitro drug release studies for developed cimetidine microspheres 
were carried out by using dissolution apparatus II paddle type 
(Electrolab TDL-08L). The drug release profile was studied in 900 
ml of 0.1 N HCl at 37μ0.50C temperature at 100 rpm. The amount 
of drug release was determined at different time intervals of 0, 1, 2, 
3, 4, 6, 8, 10 & 12 h by UV-visible spectrophotometer (Shimadzu 
UV 1800) at 218 nm [14]. 
 
Drug excipient compatibility studies 
 
The drug excipient compatibility studies were carried out by Fourier 
transmission infrared   spectroscopy (FTIR) method, Differential 
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Scanning Calorimetry (DSC), SEM and release order kinetics along 
with stability studies [12]. 
 
In vivo bioavailability studies 
  
Twelve New Zealand white rabbits of either sex were (weighing 2-3 
kg) selected for this study, all the animals were healthy during the 
period of the experiment. Animals were maintained at room 
temperature 250C, RH 45% and 12 h alternate light and dark cycle 
with 100% fresh air exchange in animal rooms, uninterrupted power 
and water supply and rabbits were fed with standard diet and water 
ad libitum. The protocol of animal study was approved by the 
institutional animal ethics committee with IAEC No: 
37/VCP/IAEC/2015/9/DBP/AE12/Rabbits. Rabbits were randomly 
divided into two groups, each group contained six animals. The 
group A rabbits were fed with cimetidine mucoadhesive 
microspheres (optimized formulation M12), group B fed with 
marketed product cimetine with equivalent dose to animal body 
weight. Blood samples (approximately 0.5 ml) were obtained with 
syringes by marginal ear vein at 0, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 20 
and 24 h post dose. During collection, blood sample has been 
mixed thoroughly with heparin in order to prevent blood clotting. 
Plasma was separated by centrifugation of the blood at 5000 rpm in 
cooling centrifuge for 5 min and stored frozen at î20ĈC until 
analysis.  
 
Preparation of plasma samples for HPLC analysis 
 
Rabbit plasma (0.5 ml) samples were prepared for chromatography 
by precipitating proteins with 2.5 ml of ice-cold absolute ethanol for 
each 0.5 ml of plasma. After centrifugation the ethanol was 
transferred into a clean tube. The precipitate was re suspended 
with 1 ml of acetonitrile by vortexing for 1 min. After centrifugation 
(5000 ă 6000 rpm for 10 min), the acetonitrile was added to the 
ethanol and the organic mixture was taken to near dryness by a 
steam of nitrogen at room temperature. Samples were 
reconstituted in 200 μl of 70% of acetonitrile and 30% water was 
injected for HPLC analysis. 
 
Determination of Cimetidine in rabbit plasma by HPLC 
method 
 
Determination of cimetidine using internal standard ranitidine by 
high performance liquid chromatography with a RP-C18 
chromatographic column, Phenomenex Kinetex (150 mm ï 4.6 mm 
i.d) and a mobile phase consisting of methanol: water (60:40 v/v) at 
a flow rate 0.8 ml/min and the wavelength detection was 225 nm.  
 
Pharmacokinetic Analysis 
 
The pharmacokinetic parameters, peak plasma concentrations 
(Cmax) and time to reach peak concentration (tmax) were directly 
obtained from concentration time data. In the present study, AUC0-t 
refers to the AUC from 0 to 24 h, which was determined by linear 
trapezoidal rule and AUC0-α refers to the AUC from time at zero 
hours to infinity. The AUC0-α was calculated using the formula 
AUC0-t + [Clast/K] where C last is the concentration in μg/ml at the 
last time point and K is the elimination rate constant. The 
pharmacokinetic parameters were performed by a non 
compartmental analysis using Win Nonlin 3.3® pharmacokinetic 
software (Pharsight Mountain View, CA USA). All values are 
expressed as the mean μSD. Statistical analysis was performed 
with Graph Pad InStat software (version 3.00, Graph Pad Software, 
San Diego, CA, USA) using one-way analysis of variance (ANOVA) 
followed by TukeyăKramer multiple comparison test. Difference 
with p<0.05 was considered statistically significant. 
 
Results and Discussion 
 
Mucoadhesive microspheres 
 
 
 
Figure 1:  Cimetidine mucoadhesive microspheres 
 
All fourteen formulations were evaluated for various micromeretic 
and physicochemical parameters and found to be within the limits. 
Among all the formulations, M12 shown best results of particle size, 
bulk density, tapped density, angle of repose and CarrÊs index. The 
percentage yield and entrapment efficiency of all the formulations 
were measured by assay method and found to be within the limits.  
The formulation M12 showed good percentage yield and 
entrapment efficiency, swelling index and mucoadhesiveness.  
 
In vitro drug release studies 
  
Cimetidine microspheres were evaluated for in vitro drug release 
studies in 0.1N HCl and the results were depicted in Table 2. The 
formulation M12 showed best drug release of 99.12% within 12 h. 
The drug release of optimized formulation M12 was in controlled 
manner when compared with innovator product cimetine i.e., 
96.12% within 1 h. 
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Table 2: In vitro cumulative % drug release of Cimetidine Mucoadhesive microspheres Formulations. 
Time in 
(h) 
M1 M2 M3 M4 M5 M6 M7 Innovator
(Cimetine 
200 mg) 
0 
0μ0 0μ0 0μ0 0μ0 0μ0 0μ0 0μ0 
0μ0
1 
16.81μ0.22 18.62μ0.52 16.44μ0.45 12.06μ0.22 10.08μ0.98 10.27μ0.14 10.6μ0.22 
96.15μ0.12
2 
35.59μ0.23 32.97μ0.16 29.61μ0.16 26.69μ0.21 21.35μ0.78 18.5μ0.18 24.36μ0.11 
---
4 
57.97μ0.32 50.16μ0.13 46.38μ0.22 43.48μ0.11 36.73μ0.76 27.75μ0.16 35.92μ0.21 
----
6 
78.61μ0.16 71.06μ0.22 59.34μ0.52 58.95μ0.13 48.64μ0.66 45.31μ0.33 60.81μ0.13 
----
8 
94.04μ0.32 83.2μ0.23 72.61μ0.34 70.53μ0.21 57.08μ0.44 68.06μ0.12 72.36μ0.33 
----
10 
93.24μ0.12 96.78μ0.32 81.65μ0.22 84.71μ0.22 68.34μ0.12 75.93μ0.22 86.89μ0.41 
----
12 
91.69μ0.23 93.56μ0.16 93.18μ0.23 90.65μ0.16 80.19μ0.32 88.72μ0.11 92.13μ0.11 
----
 
 
 
Figure 2: In-vitro cumulative % drug release of Cimetidine Mucoadhesive microspheres formulations 
 
         Table 3:  In vitro cumulative % drug release of Cimetidine mucoadhesive microspheres     formulation 
Time (h) M8 M9 M10 M11 M12 M13 M14 
0 0μ0 0μ0 0μ0 0μ0 0μ0 0μ0 0μ0 
1 9.31μ0.33 8.4μ0.12 13.96μ0.32 11.17μ0.16 12.41μ0.22 9.67μ0.12 8.22μ0.12 
2 16.48μ0.52 17.79μ0.22 24.73μ0.16 19.78μ0.15 20.76μ0.23 17.41μ0.32 14.08μ0.22 
4 26.76μ0.33 30.61μ0.43 37.62μ0.11 32.12μ0.11 35.82μ0.32 24.36μ0.16 20.7μ0.22 
6 37.72μ0.56 40.53μ0.44 53.29μ0.21 45.27μ0.16 50.62μ0.34 31.76μ0.17 37.02μ0.32 
8 50.24μ0.52 47.56μ0.52 62.4μ0.12 60.29μ0.32 67.73μ0.16 45.63μ0.22 58.79μ0.87 
10 63.21μ0.51 61.95μ0.33 72.59μ0.33 75.85μ0.16 81.09μ0.22 51.53μ0.32 71.84μ0.32 
12 78.05μ0.55 76.82μ0.22 81.23μ0.32 83.69μ0.52 99.12μ0.13 80.64μ0.16 85.39μ0.22 
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Figure 3: In vitro cumulative % drug release of Cimetidine mucoadhesive microspheres formulation 
 
In vivo bioavailability studies 
 
 
 
 Figure 4: Plasma concentrations at different time intervals for Cimetidine optimized formulation (M12) and Marketed Product Cimetine. 
 
      Table 4: Comparison of pharmacokinetic parameters of Cimetidine optimized formulation (M12) and Marketed Product 
Parameters Cimetidine Optimized formulation 
(M12) 
Marketed Product 
Cmax(ng/ml) 3.28μ0.03 4.21μ0.05 
AUC0-t(ng hr/ml) 28.15μ1.14 20.21μ1.26 
AUC0-¥ (ng hr/ml) 33.22μ1.24 25.15μ0.05 
Tmax (hr) 4.00μ0.03 1.50μ0.04 
t1/2 (hr) 7.751 μ 0.41 3.244 μ 0.01
Kel (hr-1) 2.013 μ 0.11 1.122 μ 0.33 
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Bioavailability parameters 
 
Mean plasma concentration profiles of prepared cimetidine 
optimized formulation and marketed product was presented in 
Figure 4, cimetidine optimized formulation exhibited as sustained 
release in vivo when compared with innovator tablet. All the 
pharmacokinetics parameters displayed in Table 4, cimetidine 
marketed drug was available in plasma within an hour after its oral 
administration. The Tmax of the test cimetidne was significantly 
different (p<0.05) from that of the standard. Low Tmax value for the 
reference drug (1.50μ0.04 h) indicated rapid absorption while the 
higher Tmax of the test drug (4.00μ0.03 h) suggested slower 
absorption. This delayed absorption of test preparation was most 
likely due to the sustained release of the drug. In order to estimate 
the amount of drug absorbed from the test formulation, the relative 
bioavailability was calculated from the AUC of the reference and 
test formulations (20.21μ1.26 ng. h/ml for the reference product 
versus. 28.15μ1.14 ng. h/ml for the test formulation). These results 
indicated that the test formulation increased the bioavailability of 
cimetidine in rabbits effectively.  
 
Conclusion 
 
In conclusion, it could be said that the cimetidine mucoadhesive 
microspheres developed, showed a high percentage of 
mucoadhesion and drug entrapment efficiency. Among all the 
formulations, M12 was selected as optimized formulation based on 
the physicochemical parameters and release studies. In vitro 
drug release study of formulation M12 showed 99.12% after 12 h in 
a controlled manner, which was essential for disease like peptic 
ulcer. The innovator cimetine conventional tablet showed the drug 
release of 96.15% within 1 h. This would indicate the potential of 
mucoadhesive cimetidine microspheres for use in the provision of a 
sustained anti ulcer effect. The proposed optimized formulation 
M12 depicts an effective way to prolong drug release. The in-
vivo mucoadhesive efficiency of optimized formulation was 
excellent and microspheres were retained in rabbit stomach for 
longer period of time.  
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